| Literature DB >> 29036182 |
Sara Hägglund1, Krister Blodörn1, Katarina Näslund1, Karin Vargmar2, Sara Bergström Lind3, Jia Mi3,4, Mariluz Araínga5, Sabine Riffault6, Geraldine Taylor7, John Pringle1, Jean François Valarcher1.
Abstract
Human and bovine respiratory syncytial viruses (HRSV/BRSV) are major causes of severe lower respiratory tract infections in children and calves, respectively. Shared epidemiological, clinical, pathological and genetic characteristics of these viruses make comparative research highly relevant. To characterise the host response against BRSV infection, bronchoalveolar lavage supernatant (BAL) from i) non-vaccinated, BRSV-infected ii) vaccinated, BRSV-infected and iii) non-infected calves was analysed by tandem mass spectrometry. Proteins were semi-quantified and protein expression was validated by immunoblotting. Correlations between selected proteins and pathology, clinical signs and virus shedding were investigated. Calves with BRSV-induced disease had increased total protein concentrations and a decreased number of proteins identified in BAL. The protein profile was characterised by neutrophil activation and a reduction in identified antioxidant enzymes. The presence of neutrophils in alveolar septa, the expression level of neutrophil-related or antioxidant proteins and LZTFL1 correlated significantly with disease. Citrullinated histone 3, an indicator of extracellular traps (ETs), was only detected in non-vaccinated, BRSV-infected animals. By bringing disequilibrium in the release and detoxification of reactive oxygen species, generating ETs and causing elastine degradation, exaggerated neutrophil responses might exacerbate RSV-induced disease. Neutrophil-mitigating or antioxidant treatments should be further explored.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29036182 PMCID: PMC5643112 DOI: 10.1371/journal.pone.0186594
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Animals and experimental design.
| Study | No. calves | Treatment | BRSV strain | Virology | % lung lesions | Designation | Mean BAL protein conc. (μg/μl) | Mean no. proteins identified |
|---|---|---|---|---|---|---|---|---|
| I | 5 | Non-vaccinated | 9402022 | +++ | 15.7 ± 14.5 | Susceptible_I | 0.49 | 394 |
| 5 | BRSV-ISCOM-vaccinated | 9402022 | ± | 3.8 ± 2.9 | Vaccinated | 0.19 | 547 | |
| II | 5 | Non-vaccinated | Snook | +++ | 48 ± 12.1 | Susceptible_II | 0.79 | 159 |
| 5 | None | None | - | 0 | Non-infected | 0.37 | 296 |
Fig 1Bronchoalveolar proteomes of calves.
Proteins were identified by LC-MS/MS in bronchoalveolar lavage of calves and were classified as detected at group level if identified in at least 4 out of 5 calves per group. The groups consisted of non-vaccinated, BRSV-infected calves with clinical signs of disease and high levels of virus shedding (a and b, right circles), or ISCOM-vaccinated, BRSV-infected calves with no or little clinical signs of disease and no or low levels of virus shedding (a, experiment I, left circle), or non-vaccinated, non-infected calves (b, experiment II, left circle). Protein names are provided as supplemental data (*) or in Table 1 (**).
Proteins associated with BRSV-induced disease.
| Qualitative: | Quantitative: | ||
|---|---|---|---|
| Calf experiment I | Calf experiment II | Calf experiment I | Calf experiment II |
| Actin, alpha cardiac muscle 1 | Actin, alpha cardiac muscle 1* | ||
| Actin-related protein 2/3 complex subunit 5 | Actin-related protein 2/3 complex subunit 5* | ||
| Adenylyl cyclase-associated protein** | |||
| Alpha-1B-glycoprotein | Alpha-1B-glycoprotein* | ||
| Annexin A1 * | |||
| Azurocidin | Azurocidin | Azurocidin* | |
| Beta-2-microglobulin* | |||
| Beta-defensin (2/8/10) | Beta-defensin (2/8/10/13) | Beta-defensin (10*) | Beta-defensin (2**/8*/10*/12**) |
| BRSV (M/M2-1/N /P) | BRSV(M*/M2-1*/N* /P**) | ||
| Calponin-2 | |||
| Cathelicidin (4/5/7) | Cathelicidin (5) | Cathelicidin (1***/3*/4*/5**) | Cathelicidin (1**/2*/3*/4**/5**/6*/7**) |
| Cathepsin (G/L2) | Cathepsin (G like) | Cathepsin (G**/L2*) | Cathepsin (G**) |
| CD14 | CD14** | ||
| CD177 | CD177** | ||
| CD44 | |||
| Complement factor properdin | Complement factor properdin** | ||
| Coronin-1A** | |||
| Cystatin-C** | |||
| ECM1 protein | |||
| EF-hand domain-containing protein D2 | EF-hand domain-containing protein D2** | ||
| Elastase | Elastase | Elastase* | Elastase* |
| Folate receptor alpha | Folate receptor alpha | Folate receptor alpha* | |
| Fructose-bisphosphate aldolase* | |||
| Glucose-6-phosphate isomerase* | |||
| Glyceraldehyde-3-phosphate dehydrogenase* | |||
| Granulin | Granulin | Granulin** | Granulin** |
| Haptoglobin* | Haptoglobin* | ||
| Hematopoietic cell-specific Lyn substrate 1 | Hematopoietic cell-specific Lyn substrate 1 | Hematopoietic cell-specific Lyn substrate 1* | |
| High mobility group protein B2* | |||
| Histone (H2A/H2AB/H2B) | Histone (H1e/H1.1/H1.2/H1.3/H2A.J/H2B 1/H2B 1-K/ H3.2) | Histone (H1.3*/H2A*/H2A 2-C*/H2B*/H3.1*/H4*) | Histone (H1e*/H1.1*/H1.2*/ H2AC*/H2AJ*) |
| Ig lambda chain V-I region BL2-like | Ig lambda chain V-I region BL2-like** | ||
| Ig like V-set | Ig like V-set* | ||
| Inter-alpha-trypsin inhibitor heavy chain H4 | |||
| Lactotransferrin** | Lactotransferrin* | ||
| Lingual antimicrobial peptide | Lingual antimicrobial peptide* | ||
| L-serine dehydratase/L-threonine deaminase | L-serine dehydratase/L-threonine deaminase | L-serine dehydratase/L-threonine deaminase** | |
| Lymphocyte cytosolic protein 1 | Lymphocyte cytosolic protein 1* | ||
| Lymphocyte-specific protein 1 | Lymphocyte-specific protein 1 | ||
| Macrophage migration inhibitory factor | |||
| Matrix metalloproteinase-9*** | |||
| MSLN protein | |||
| Myeloperoxidase | Myeloperoxidase** | Myeloperoxidase* | |
| Neutrophilic granule protein-like | Neutrophilic granule protein-like* | ||
| Nucleobindin 2 | Nucleobindin 2** | ||
| Olfactomedin 4** | |||
| Pentraxin-related protein PTX3 | Pentraxin-related protein PTX3** | ||
| Peptidoglycan recognition protein 1** | Peptidoglycan recognition protein 1* | ||
| Primary amine oxidase, liver isozyme | |||
| Protein FAM49B | |||
| Protein S100-A9 | Protein S100-A9 | Protein S100 (A8**/A9*) | |
| Proteinase 3 | Proteinase 3** | ||
| Ras-related C3 botulinum toxin substrate 2* | |||
| Regakine-1 | |||
| Resistin | Resistin* | Resistin** | |
| Rho GDP-dissociation inhibitor 2 | Rho GDP-dissociation inhibitor 2* | ||
| Secretoglobin family 1D member | |||
| SERPINB4 protein | SERPINB4 protein** | ||
| Serum amyloid A protein (3.2) | Serum amyloid A protein (1/3.2) | Serum amyloid A protein (1*/3.2**) | |
| Spleen trypsin inhibitor I | Spleen trypsin inhibitor I*** | ||
| Sulfhydryl oxidase* | |||
| Transaldolase | Transaldolase*** | ||
| Uteroglobin | |||
| Transcobalamin 1*** | |||
| Transketolase** | |||
| Uncharacterised (G5E604 | |||
| Uncharacterised (ENSEMBL:ENSBTAP00000014147d)* | |||
aProteins were detected in bronchoalveolar lavage from non-infected and/or BRSV-infected calves by LC-MS/MS and semi-quantified by label free analysis. Grey highlight; proteins associated with BRSV-induced disease, in both animal experiments I and II
bUniquely detected at group level in non-vaccinated, BRSV-infected, susceptible calves (i.e. detected in at least 4 out of 5 non-vaccinated, BRSV-infected, susceptible calves and in less than 4 ISCOM-vaccinated, BRSV-infected, protected calves (Experiment I) or non-infected calves (Experiment II)).
cDetected at significantly higher expression levels in non-vaccinated, BRSV-infected, susceptible calves compared to in ISCOM-vaccinated, BRSV-infected, protected calves (Experiment I) or non-infected calves (Experiment II)).
dProtein identification number, uncharacterized protein, no gene identified
Statistically significant differences are indicated by asterisks; p≤0.05(*); p≤0.01 (**); p≤0.001 (***).
Fig 2Semi-quantification of selected proteins involved in processes that were affected by BRSV-infection.
Proteins were detected in bronchoalveolar lavage from non-vaccinated, BRSV-infected calves with clinical signs of disease and high levels of virus shedding (black bars) and/or in BRSV-ISCOM-vaccinated, BRSV-infected calves with no or little clinical signs of disease and no or low levels of virus shedding (a, experiment I, grey bars), and/or non-vaccinated, non-infected calves (b, experiment II, grey bars). Proteins were identified by LC-MS/MS and semi-quantified by label-free analysis. Statistically significant differences are indicated by asterisks; p≤0.05(*); p≤0.01 (**); p≤0.001 (***). Proteins were selected based on being related to neutrophil activation and chemotaxis or detoxification of reactive oxygen species: biological processes identified by protein pathway analysis.
Fig 3Association of citrullinated histone 3 with BRSV disease.
Detection of citrullinated histone 3 by Western blot in bronchoalveolar lavage from BRSV-infected calves with clinical signs of disease and high levels of virus shedding (k-o and D1-D5) compared to that in BRSV-ISCOM-vaccinated, BRSV-infected calves with no or little clinical signs of disease and no or low levels of virus shedding (a-e, Experiment I), or non-vaccinated, non-infected calves (E1-E5, Experiment II).
Fig 4Detection of citrullinated histone 3 and myeloperoxidase in serially diluted BAL.
Detection of citrullinated histone 3 (a) and myeloperoxidase (b) by dotblot in bronchoalveolar lavage (BAL) from BRSV-infected calves with clinical signs of disease and high levels of virus shedding (k-o and D1-D5) compared to that in BRSV-ISCOM-vaccinated, BRSV-infected calves with no or little clinical signs of disease and no or low levels of virus shedding (a-e, Experiment I), or non-vaccinated, non-infected calves (E1-E5, Experiment II). The proteins were selected based on being present in neutrophil extracellular traps, incriminated to be important in the pathogenesis of RSV [30].
Fig 5Scores of neutrophilic infiltration of alveolar septa in BRSV-infected calves.
HE stained sections. a) score 0 (vaccinated calf a, experiment I), b) score 1 (vaccinated calf b, experiment I), c) score 2 (non-vaccinated, BRSV-infected calf l, experiment I) and d) score 3 (non-vaccinated, BRSV infected calf D5, experiment II). Lesions are examples of neutrophil scores and not representative for the overall inflammation regarding exudate and consolidation.
Correlations (Spearman’s rho) between relative expression level of selected proteins in bronchoalveolar lavage from calves six days post BRSV infection, BRSV-induced disease and presence of neutrophils in alveolar septa.
| Protein | Lung lesion exent | Clinical score | Virus shedding | Neutrophils in septa |
|---|---|---|---|---|
| Elastase | 0.78, p = 0.007 | 0.77, p = 0.009 | 0.80, p = 0.006 | 0.70, p = 0.025 |
| Myeloperoxidase | 0.69, p = 0.028 | 0.67, p = 0.036 | 0.79, p = 0.006 | 0.80, p = 0.005 |
| Resistin | 0.78, p = 0.008 | 0.85, p = 0.002 | 0.88, p = 0.001 | 0.89, p = 0.001 |
| S100-A9 | 0.75, p = 0.013 | 0.85, p = 0.002 | 0.88, p = 0.001 | 0.83, p = 0.003 |
| Superoxide dismutase | -0.70, p = 0.024 | -0.79, p = 0.007 | -0.82, p = 0.004 | -0.78, p = 0.009 |
| Gluthathione peroxidase | n.s. | -0.64, p = 0.048 | -0.74, p = 0.014 | -0.73, p = 0.018 |
| Peroxiredoxin-6 | n.s. | -0.69, p = 0.027 | -0.74, p = 0.015 | n.s. |
| Leucine Zipper TFL1 | n.s. | -0.76, p = 0.010 | -0.71, p = 0.021 | n.s. |
aProteins were identified and semi-quantified by LC-MS/MS including label free analysis, in bronchoalveolar lavage (BAL) from non-vaccinated, BRSV-infected calves with clinical signs of disease and high levels of virus shedding (n = 5) and in BRSV-ISCOM-vaccinated, BRSV-infected animals with no or little clinical signs of disease and no or low levels of virus shedding (n = 5).
bCorrelation of protein with extent of pathologic lung lesions at the day of BAL collection, post infection day (PID) 6
cCorrelation of protein with sum of clinical scores PID 6
dCorrelation of protein with quantity of BRSV-RNA detected in nasal swabs PID 6
eCorrelation of protein with extent of neutrophils in alveolar septa on one histological section from the right cranial lobe (from areas with macroscopic consolidation, if present) on PID 6. The presence of neutrophils was graded between 0 and 3.
n.s; not satistically significant (p>0.05)